🌈 Make a Tribute to Honor a Dog You Love This Rainbow Bridge Day – Now Through August 28th, 2026.

01669-A: Determining the Role of Bacterial Infection in Complications after Chemotherapy

Since cancer cells lack the normal response to ‘stop replicating’ signals, the approach to treatment of this cellular proliferation is use of chemotherapeutic agents that target rapidly dividing cells. However, the use of chemotherapy also targets the patient’s own normal rapidly dividing cells (e.g., bone marrow and gastrointestinal tract). Therefore, patients receiving chemotherapy are often […]

01843: Further Investigation of the Genes Controlling Canine Leukemia to Properly Diagnose and Control the Disease

Grant Status: Closed Grant Amount: $131,265 Matthew Breen, PhD; North Carolina State University January 1, 2013 – December 31, 2014 Sponsor(s): American German Shepherd Dog Charitable Foundation, Inc., Cairn Terrier Club of America, Inc., English Cocker Spaniel Club of America, English Setter Association of America, Inc., Golden Retriever Foundation, Mastiff Club of America, Poodle Club […]

03283: Investigating the Immune and Cytoreductive Activities of Gilvetmab Alone and in Combination with Indoleamine 2,3-Dioxygenase Inhibition in Canine Urothelial Carcinoma

Bladder cancer in dogs causes longstanding pain and discomfort with eventual death from the inability to urinate. In some dogs diagnosed with bladder cancer, supportive treatment with urinary catheters to alleviate urinary obstruction and intravenous fluids to support general kidney health can improve quality of life for a short period of time. However, few treatment […]

00888-A: Generation of Canine Single Chain Fragment Variable Antibody Libraries for the Identification and Targeting of Tumor-Associated Antigens in the Dog

Cancer is the leading cause of disease related death in our current canine pet population. The mainstay of cancer therapy is the systemic administration of chemotherapeutic agents that inhibit cell division and induce cell death. These agents however are not tumor-specific and frequently cause adverse side effects which limit the dose that can be given […]

01410A: Positional Cloning of Histiocytic Sarcoma (HS) in the Bernese Mountain Dog (BMD) and Flat Coated Retriever (Part A – See also 01410B)

Grant Status: Closed Grant Amount: $50,000 Elaine A Ostrander, PhD; National Human Genome Research Institute January 1, 2011 – December 31, 2011 Sponsor(s): American Bouvier des Flandres Club – Bouvier Health Foundation, American Bullmastiff Association, American German Shepherd Dog Charitable Foundation, Inc., American Miniature Schnauzer Club, Inc., Australian Shepherd Health & Genetics Institute, Australian Terrier […]

02244-A: Beyond Peto’s Paradox with the Geriatric Peromyscus

A Collaborative Grant between Triangle Center for Evolutionary Medicine (TriCEM) and AKC Canine Health Foundation (CHF) Cancer is a heterogeneous or widely divergent collection of diseases with a similarly wide variety of outcomes, natural histories and responses to therapy. While new medical and genomic data have shed light on the molecular mechanisms causing cancer, why […]

01426: Personalized Medicine for the Treatment of Canine Mast Cell Tumors

While surgery remains the mainstay of treatment for canine mast cell tumors (MCT), surgery alone is not curative in some cases, and not possible in other cases. Medical therapy remains an important component of MCT therapy. New drugs that affect signaling through the KIT growth factor receptor are showing considerable promise for the treatment of […]